Merck & Co (MRK) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating noninferiority for the 13 serotypes contained in both vaccines. A point of differentiation is that V114 also induced an immune response in infants for two additional disease-causing serotypes (22F and 33F) which are not contained in PCV13.
Keep in mind that a few months ago this asset received the coveted